Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Nyxoah Announces Participation in theCantor 2021 Virtual Global Healthcare Conference


GlobeNewswire Inc | Sep 13, 2021 04:30PM EDT

September 13, 2021

Nyxoah Announces Participation in theCantor 2021 Virtual Global Healthcare Conference

Mont-Saint-Guibert(Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (Nyxoah or the Company), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conference on Tuesday, September 28, 2021, with a virtual presentation at 4:00 pm CET/10:00 am ET.

A live webcast and replay of this event will be available on the Companys investors relations website at https://investors.nyxoah.com/

About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoahs lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the worlds most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah is seeking for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

Contacts:NyxoahFabian Suarez, Chief Financial Officerfabian.suarez@nyxoah.com+32 10 22 24 55

Gilmartin GroupVivian Cervantesvivian.cervantes@gilmartinir.com

Attachment

-- ENGLISH - NYXH Announces Cantor HC - FINAL







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC